Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) recently corrected previously reported interim data (responder analysis) from a phase II study of VX-809 and Kalydeco. Vertex also provided some additional data from the study.
The interim data from the phase II study showed improvements in lung function in adults with cystic fibrosis (CF) who had two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The interim data was on 37 patients who were treated … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards